2022
DOI: 10.1056/evidoa2200092
|View full text |Cite
|
Sign up to set email alerts
|

A Randomized Trial of PHOTOdynamic Surgery in Non–Muscle-Invasive Bladder Cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
11
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 28 publications
(11 citation statements)
references
References 26 publications
0
11
0
Order By: Relevance
“…Despite reported benefit in improved tumor detection, adoption of BLC remains limited due to the increased cost of specialized cystoscopic equipment and imaging agent, as well as clinical workflow demand to instill the imaging agent into the bladder 1 hour in advance of BLC. Moreover, a recent randomized controlled trial of BLC versus WLC failed to demonstrate a benefit to recurrence-free survival at 3 years, but did confer some additional cost (Heer et al 2022). Cost-effective, noninvasive, and easily adoptable adjunct imaging technologies are needed to address the diagnostic shortcomings of both WLC and BLC.…”
Section: Introductionmentioning
confidence: 99%
“…Despite reported benefit in improved tumor detection, adoption of BLC remains limited due to the increased cost of specialized cystoscopic equipment and imaging agent, as well as clinical workflow demand to instill the imaging agent into the bladder 1 hour in advance of BLC. Moreover, a recent randomized controlled trial of BLC versus WLC failed to demonstrate a benefit to recurrence-free survival at 3 years, but did confer some additional cost (Heer et al 2022). Cost-effective, noninvasive, and easily adoptable adjunct imaging technologies are needed to address the diagnostic shortcomings of both WLC and BLC.…”
Section: Introductionmentioning
confidence: 99%
“…Since WLC may miss at least 20% of bladder cancers [3], adjunct image modality like photodynamic diagnosis (PDD), or blue light cystoscopy (BLC) can be indicated to increase the detection sensitivity of cystoscopy [4]. Although BLC results in a better sensitivity for bladder tumors (80-99%) than WLC (70-90%), both image modalities suffer from poor to moderate specificities (34-70%) [5][6][7] and the additive benefit of BLC for recurrence free survival is limited [8].…”
Section: Introductionmentioning
confidence: 99%
“…Although BLC results in a better sensitivity for bladder tumors (92.3-99%) than WLC (80-90%), both image modalities suffer from poor specificities (34-70%) [5][6][7]. In a recent randomized-controlled trial, BLC failed to demonstrate a benefit to recurrence free survival [8]. BLC requires instillation of a photo-sensitive fluorescence agent, costly specialized equipment, and additional provider training and experience.…”
Section: Introductionmentioning
confidence: 99%